Huge need for RNA/DNA next generation therapeutic delivery vehicles
RNA-based COVID 19 vaccines and the approval of CRISPR clinical trials have changed the regulatory paradigm and drive an unprecedented growth in the lipid-nanoparticle delivery field. We are developing new DNA and RNA - based medications together with the delivery vehicles which lead these next generation therapeutics to their desired cell targets.
Our team generates and in vivo screens thousands of different barcoded nanoparticles to lead RNA/DNA therapeutics to desired target sites.
While new RNA and DNA therapeutics are being developed, nanoparticle-based delivery vehicles to target these molecules to specific cells are still limited.
Nanoparticle screening is currently limited as a large number of variables can affect the bio-distribution of these delivery vehicles. These variables include: size, lipid composition, surface charge, ligand selection and more.
Founded in 2017, Barcode has developed and in vivo screened barcoded nanoparticles as delivery tools for different therapeutics.
We integrate state-of-the-art advances in lipid nanoparticle technologies as drug delivery tools, with formulation screening, tissue analysis and AI, to generate the next generation of RNA and DNA-based therapies.
Our scientific and research team
Barcode nanotech's management & researchers and scientists.
CEO AND CO-FOUNDER
Ronen Eavri, Ph.D. MBA
Leading new product development in pharmaceutical and medical device companies for over 10 years (formally: J&J and D-Pharm) .
Scientific education from the Hebrew University, Technion and MIT.
CTO AND CO-FOUNDER
Annie Sabbah, Ph.D.
Former CTO of MPT Diagnostics and Lab Research Manager at Rambam Campus (Technion). Expert in microparticles and molecular biology.
Scientific education from the Technion.
R&D TEAM LEADER
Felix Badinter M.Sc.
M.Sc. in Biotechnology from the Technion.
Over 8 years of industrial experience in Research and Development in the fields of biotech and nanotechnology.
ANALITICAL CHEMISTRY LEAD
Valeria Rukhman Ph.D.
Ph.D. in Biochemistry from the faculty of Chemistry of the Technion.
Over 15 years of experience in pharmaceutical QC laboratories.
Or Rosen M.Sc.
M.Sc. in Biotechnology from the Tel-Hai.
Experienced in various chemical and biological processes.